CD52 and congenital rubella syndrome: Incubation of whole blood with an anti-CD28 (clone ANC28.1/5D10) super-agonist or with alemtuzumab (anti-CD52) positive controls resulted in the robust release of TNFα, IL-6, and IL-1β, cytokines associated with CRS (35, 36).